Cibc World Market Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 685,308 shares of the company’s stock after selling 18,584 shares during the period. Cibc World Market Inc.’s holdings in Johnson & Johnson were worth $181,428,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Outlook Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the second quarter worth $28,000. Matrix Trust Co raised its position in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the period. Navigoe LLC raised its position in Johnson & Johnson by 60.4% in the third quarter. Navigoe LLC now owns 146 shares of the company’s stock valued at $38,000 after purchasing an additional 55 shares during the period. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson during the second quarter worth about $43,000. Finally, Hanseatic Management Services Inc. acquired a new position in shares of Johnson & Johnson during the third quarter worth about $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Price Performance
Shares of NYSE JNJ opened at $278.42 on Wednesday. The stock has a market cap of $670.23 billion, a P/E ratio of 42.18, a P/E/G ratio of 2.79 and a beta of 0.22. The firm’s 50-day simple moving average is $267.31 and its 200 day simple moving average is $250.38. Johnson & Johnson has a fifty-two week low of $198.53 and a fifty-two week high of $290.25. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio (DPR) is 81.21%.
Analyst Ratings Changes
JNJ has been the subject of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Johnson Rice cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a report on Thursday, October 15th. Morgan Stanley cut their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a report on Thursday, October 15th. Finally, Raymond James Financial set a $280.00 price objective on Johnson & Johnson in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $275.92.
View Our Latest Research Report on JNJ
Key Headlines Impacting Johnson & Johnson
Investors following JNJ have been watching these headlines:
- Positive Sentiment: J&J’s planned acquisition of Ollin Biosciences adds a Phase 3 candidate for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. The deal includes $2.2 billion upfront and up to about $1.1 billion in milestone payments; Blackstone is expected to provide $750 million toward development. UBS sees the asset as a potential growth driver beyond 2030. J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition UBS on Ollin as a Growth Driver
- Neutral Sentiment: The Ollin acquisition strengthens J&J’s ophthalmology portfolio, but its late-stage drug would enter a competitive market and still faces clinical and commercial execution risks. J&J Bets $2.2B on Ollin’s Vision Loss Drug
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J related to its talc baby powder, adding to ongoing litigation concerns. Separately, Pomerantz LLP said it is investigating claims on behalf of J&J investors; an investigation is not a finding of wrongdoing, but may add uncertainty. Louisiana Appeals Court Upholds Damages in Mesothelioma Case Pomerantz Investor Alert
Insider Activity at Johnson & Johnson
In related news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This trade represents a 43.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.16% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Read More
- Five stocks we like better than Johnson & Johnson
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
